Navigation Links
Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
Date:9/17/2008

ne tablets in delaying the development of definite MS.

In the study, Cladribine tablets are given in two or four treatment cycles in the first year, with each cycle consisting of once daily administration for four to five consecutive days, which means study patients take Cladribine tablets for only 8 to 20 days during that year. In the second year, two treatment cycles are administered to all patient groups.

The primary endpoint of the ORACLE MS trial is time to conversion to MS, according to the McDonald criteria. Other endpoints include time to conversion to clinically definite MS according to the Poser criteria (the main secondary endpoint), assessments of MRI brain scans, and disability progression.

Approximately 200 medical centers globally are expected to participate in this trial.

(1) CLARITY: Cladribine Tablets Treating MS Orally

About Cladribine tablets

Merck Serono's proprietary oral formulation of Cladribine is currently being evaluated in Phase III as a treatment for patients with relapsing forms of multiple sclerosis (MS). Cladribine is a small molecule that may interfere with the behavior and the proliferation of certain white blood cells, particularly lymphocytes, which are thought to be involved in the pathological process of MS.

About Rebif(R)

Rebif(R) (interferon beta-1a) is a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS) and is similar to the interferon beta protein produced by the human body. The efficacy of Rebif(R) in chronic progressive MS has not been established. Interferons are thought to help modulate the body's immune system and reduce inflammation. The exact mechanism is unknown.

Rebif(R), which was approved in Europe in 1998 and in the US in 2002, is registered in more than 80 countries worldwide. Rebif(R) has been proven to delay the progression of disability, reduce the frequency of relapses and reduce MRI lesion activity and area*. Rebif(
'/>"/>

SOURCE Merck Serono International S A
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
4. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
5. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
6. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
7. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
8. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
9. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
10. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
11. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , Mar. 27, 2015 Research and ... the addition of the "European Laboratory Information ... System), by Type (Clinical Pathology Laboratory Information System, ... 2019" report to their offering. ... to grow at a CAGR of 7.6% from ...
(Date:3/31/2015)... N.J. , March 31, 2015  PAION, ... today announced the initiation of a U.S. Phase ... for procedural sedation in patients undergoing colonoscopy. ... faster onset of sedation and greater procedural success ... profile and patients experienced rapid recovery from sedation ...
(Date:3/30/2015)... , 31 mars 2015  Une équipe de scientifiques ... atomique d,un récepteur de surface cellulaire qui ... de thromboses. Contre toute attente, cette recherche ... caractéristiques structurelles qui remettent en cause les ... les récepteurs couplés aux protéines G (RCPG) ...
Breaking Medicine Technology:European Laboratory Information System Market Report 2015: Germany holds a larger share of the laboratory information systems market 2European Laboratory Information System Market Report 2015: Germany holds a larger share of the laboratory information systems market 3PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy 2PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy 3PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy 4De nouvelles structures moléculaires remettent en cause les idées conventionnelles concernant l'action des médicaments sur les récepteurs 2De nouvelles structures moléculaires remettent en cause les idées conventionnelles concernant l'action des médicaments sur les récepteurs 3
... ,, BETHESDA, Md. , June 30 ... an innovator in biotechnology for therapy in diabetes, ... and regulatory consulting services to food, supplement, biotechnology ... subsidiary, Biospherics Incorporated, has signed a license agreement ...
... 30 Xoft, the leading provider of FDA-cleared ... Center of Hoag Memorial Hospital Presbyterian in Newport ... Brachytherapy, eBx™ System to support the launch of its ... progressive, comprehensive approach to breast cancer treatment. The first ...
Cached Medicine Technology:Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy 2Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy 3Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy 4Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy 5Hoag Breast Care Center Installs Xoft Electronic Brachytherapy System for IORT Program 2Hoag Breast Care Center Installs Xoft Electronic Brachytherapy System for IORT Program 3Hoag Breast Care Center Installs Xoft Electronic Brachytherapy System for IORT Program 4
(Date:3/31/2015)... (PRWEB) March 31, 2015 Horizon Blue ... today that its efforts to combat health insurance fraud ... a combination of monies recovered and losses avoided -- ... total since Horizon BCBSNJ created its fraud fighting, Special ... BCBSNJ’s anti-fraud efforts have saved members $261 million. ...
(Date:3/31/2015)... An individual’s meniscus (cushion in the knee) ... leg providing stability, load bearing and preservation of the ... Day meeting of the American Orthopaedic Society for Sports ... the potential for biologic healing following a meniscus tear. ... of meniscus tears when a root repair is performed ...
(Date:3/31/2015)... 2015 Burns Engineering announces 3-Day Quick Ship ... the Food & Beverage, Pharmaceutical and Biotech markets. These field ... compliant and are now available as part of Burns’ Quick ... The S01 and S03 with 1/8” and 1/4” ... connections used in process lines 1/4” and larger. Sensors ...
(Date:3/31/2015)... The report “Coagulation/Hemostasis Analyzer Market By ... (APTT, Prothrombin Time/INR, D-Dimer, Fibrinogen), Technology (Mechanical, Optical), ... and studies the major market drivers, restraints, opportunities ... the Rest of the world (RoW). , ... reach $3.58 billion by 2019 from $2.4 billion ...
(Date:3/31/2015)... March 31, 2015 DentalXChange, ... specializes in providing online solutions to connect ... it has achieved full accreditation for the ... Accreditation Program (HNAP) from the Electronic Healthcare ... HNAP accreditation runs in two-year increments and ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Saves Members, Health System a Record $45.4 Million through Anti-fraud Efforts 2Health News:New Way to Evaluate Meniscus Tear Outcomes 2Health News:Burns Engineering Now Offers 3-Day Quick Ship on Sanitary RTDs and Thermocouples 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 3Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 4Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 2Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 3
... HealthDay Reporter , MONDAY, Dec. 12 (HealthDay News) -- Toddlers ... finding that researchers say may provide a clue to the ... is largely an involuntary process that helps keep the eyes ... are closed, you are temporarily blinded. And throughout a typical ...
... infrastructure, inefficient distribution channels and disruptive black markets must ... with the growing problem of malaria, according to a ... Systems and Management . Historically, malaria is humanity,s ... some regions it remains the biggest infectious threat in ...
... , MONDAY, Dec. 12 (HealthDay News) -- Acupuncture may ... according to a new study. Cancer drugs called ... nerves, especially in the calves and feet, resulting in ... is no effective treatment for the condition, called chemotherapy ...
... Reporter , MONDAY, Dec. 12 (HealthDay News) -- When she was ... Madeline Mann was the world,s smallest surviving baby. At the ... world,s tiniest infant, weighing in at 0.57 pounds. She was one ... the neonatal intensive care unit at Loyola University Medical Center in ...
... Reinberg HealthDay Reporter , MONDAY, Dec. 12 ... colon, breast, prostate and cervical cancer even though guidelines ... finds. As the population of the United States ... will be a continuing battle, experts say. "In an ...
... Patients who receive a blood ... to treat leukemia and other blood diseases are more likely ... disease, a condition caused by the donor cells attacking the ... a donor,s bone marrow, rather than from blood stem cells ...
Cached Medicine News:Health News:Blink Patterns May Be a Window Into Autistic Mind 2Health News:Blink Patterns May Be a Window Into Autistic Mind 3Health News:A logistics approach to malaria in Africa 2Health News:Acupuncture Might Ease Chemotherapy Pain 2Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 2Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 3Health News:Are Too Many Older People Screened for Cancer? 2Health News:Are Too Many Older People Screened for Cancer? 3Health News:Bone marrow and blood stem cell transplant survival rates equal, when donor is unrelated to patient 2
TEW hooked micro-retractor blade set....
... blades are designed for the retraction of nerves, ... the brain. Equalizes brain retraction pressure. Decreases shear ... Used in conjunction with the Budde Halo Retractor. ... wide and 2 mm and 4 mm wide. ...
Mini-Vise....
The Budde Halo Retractor Side Rail Support is designed for the adaptation and attachment of the Budde Halo Brain Retractor System to the operating room table when a conventional skull clamp is not us...
Medicine Products: